Athira Pharma, Inc.: insider trades · United States · SEC (Form 4)

About Athira Pharma, Inc.

Athira Pharma, Inc. is a U.S.-listed biopharmaceutical company traded on NASDAQ and based in the United States. For French-speaking investors, the company fits the profile of a clinical-stage biotech: it focuses its capital and scientific efforts on discovering and developing novel therapies for neurodegenerative diseases and other high-unmet-need indications. Athira’s current strategy is centered on proprietary small-molecule programs, led by ATH-1105, which the company positions as a potential treatment for Alzheimer’s disease, Parkinson’s disease, Parkinson’s disease dementia, amyotrophic lateral sclerosis, neuropathic pain, and other neurodegenerative disorders. Its intellectual-property portfolio also includes other small-molecule candidates, including ATH-1020, as well as legacy assets such as fosgonimeton, underscoring a pipeline built around internal research, platform science, and selective asset development. Founded in the late 2010s, Athira was established around a neuroscience-driven R&D approach aimed at neuroprotection and pathways implicated in neuronal degeneration. The company does not yet have meaningful commercial revenue, which places it squarely in the development-stage biotech category and makes it highly dependent on clinical execution, capital access, and regulatory outcomes. Competitively, Athira is a niche specialist rather than a broad pharmaceutical platform, and it operates in a crowded field that includes both large pharma companies and numerous CNS-focused biotech peers. Its potential differentiation lies in scientific selectivity, the quality of its development candidates, and the breadth of its patent estate, with patent coverage pursued in the United States and multiple international jurisdictions. Geographically, Athira’s footprint is primarily U.S.-based, with research, development, corporate, and investor-relations activities concentrated in the United States, while the company seeks protection for key assets abroad as well. Recent highlights include a December 2025 corporate presentation that emphasized ATH-1105 and referenced potential strategic transactions or partnerships around lasofoxifene, alongside a sizeable private placement announced in the same period involving common shares, pre-funded warrants, and accompanying warrants. Recent SEC Form 4 filings also point to ongoing insider transaction activity, and the company disclosed a 10-for-1 reverse stock split completed in September 2025, which is relevant for assessing capital structure, dilution dynamics, and trading optics. Overall, Athira Pharma should be viewed as a speculative small-cap biotech with a catalyst-driven profile, where valuation is primarily tied to clinical progress, financing milestones, and strategic optionality rather than near-term earnings power.